JP2019511567A5 - - Google Patents

Download PDF

Info

Publication number
JP2019511567A5
JP2019511567A5 JP2018561933A JP2018561933A JP2019511567A5 JP 2019511567 A5 JP2019511567 A5 JP 2019511567A5 JP 2018561933 A JP2018561933 A JP 2018561933A JP 2018561933 A JP2018561933 A JP 2018561933A JP 2019511567 A5 JP2019511567 A5 JP 2019511567A5
Authority
JP
Japan
Prior art keywords
nox
pharmaceutical composition
composition according
configuration
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018561933A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019511567A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/018233 external-priority patent/WO2017143104A1/en
Publication of JP2019511567A publication Critical patent/JP2019511567A/ja
Publication of JP2019511567A5 publication Critical patent/JP2019511567A5/ja
Pending legal-status Critical Current

Links

JP2018561933A 2016-02-16 2017-02-16 脳卒中と関連する低酸素状態の調節 Pending JP2019511567A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662296009P 2016-02-16 2016-02-16
US62/296,009 2016-02-16
PCT/US2017/018233 WO2017143104A1 (en) 2016-02-16 2017-02-16 Modulation hypoxia associated with stroke

Publications (2)

Publication Number Publication Date
JP2019511567A JP2019511567A (ja) 2019-04-25
JP2019511567A5 true JP2019511567A5 (enExample) 2020-04-02

Family

ID=58191670

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018561933A Pending JP2019511567A (ja) 2016-02-16 2017-02-16 脳卒中と関連する低酸素状態の調節

Country Status (15)

Country Link
US (3) US20200276265A1 (enExample)
EP (1) EP3416673B1 (enExample)
JP (1) JP2019511567A (enExample)
KR (1) KR20180123034A (enExample)
CN (1) CN109069582A (enExample)
AU (1) AU2017219869A1 (enExample)
BR (1) BR112018016829A2 (enExample)
CA (1) CA3014651A1 (enExample)
DK (1) DK3416673T3 (enExample)
ES (1) ES2939181T3 (enExample)
IL (1) IL261178A (enExample)
MX (1) MX2018009881A (enExample)
RU (1) RU2018131359A (enExample)
SG (2) SG10202007517TA (enExample)
WO (1) WO2017143104A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3922643A1 (en) * 2013-01-07 2021-12-15 Omniox, Inc. Polymeric forms of h-nox proteins
WO2020037052A1 (en) 2018-08-15 2020-02-20 Omniox, Inc. H-nox proteins for treating cardiovascular and pulmonary conditions
AU2022328718A1 (en) * 2021-08-18 2025-01-09 Omniox Inc. H-nox proteins for organ preservation

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4873192A (en) 1987-02-17 1989-10-10 The United States Of America As Represented By The Department Of Health And Human Services Process for site specific mutagenesis without phenotypic selection
US6054427A (en) 1997-02-28 2000-04-25 The Regents Of The University Of California Methods and compositions for optimization of oxygen transport by cell-free systems
AU2002346686A1 (en) * 2001-12-07 2003-06-23 Intermune, Inc. Compositions and method for treating hepatitis virus infection
US20030153491A1 (en) 2002-01-11 2003-08-14 Winslow Robert M. Methods and compositions for oxygen transport comprising a high oxygen affinity modified hemoglobin
EP2463295A1 (en) 2006-05-22 2012-06-13 The Regents of The University of California Compositions and methods for the delivery of oxygen
EP3922643A1 (en) * 2013-01-07 2021-12-15 Omniox, Inc. Polymeric forms of h-nox proteins

Similar Documents

Publication Publication Date Title
Brines The therapeutic potential of erythropoiesis-stimulating agents for tissue protection: a tale of two receptors
TWI648401B (zh) 生長分化因子15(gdf-15)構築體
US12303550B2 (en) Neuroprotective peptides
Bansal et al. Interferon gamma peptidomimetic targeted to hepatic stellate cells ameliorates acute and chronic liver fibrosis in vivo
CN102596217B (zh) 经修饰的血管活性肠肽
AU2017202919B2 (en) Pegylated Apelin and uses thereof
JP2017529059A5 (enExample)
JP2002531420A (ja) 経血液脳関門用物質運搬体ペプチド
US6670323B1 (en) Reduced side-effect hemoglobin compositions
Bidwell 3rd Novel protein therapeutics created using the elastin-like polypeptide platform
WO2010013012A9 (en) Hypothermia inducing polypeptides and uses thereof
US11529424B2 (en) Synthetic bioconjugates
CN106699896A (zh) 一种可自组装成水凝胶的肿瘤杀伤性多肽及其应用
ES2360598T3 (es) Receptores de linfocitos t que se unen especificamente a vygfvracl-hla-a24.
CN117186239A (zh) 融合蛋白及其应用
JP4933440B2 (ja) 経皮デリバリーのための薬剤組成物
US20100004165A1 (en) Novel Protein Transduction Domains and Uses Therefor
KR100935030B1 (ko) 새로운 세포투과성 펩타이드 및 이를 이용한 생물학적 활성물질의 전달 방법
CN106163569A (zh) 活化的神经降压素分子及其用途
RU2018131359A (ru) Модуляция гипоксии, ассоциированной с инсультом
CN114644687A (zh) 一种可拮抗rbm25蛋白rna结合活性的多肽rbip-21及其应用
WO2016140983A1 (en) Compositions and methods for pegylated il-11
WO2018219301A1 (zh) 一种PDGFRβ靶向性肿瘤坏死因子相关凋亡诱导配体变异体及其制备方法和用途
WO2014063239A1 (en) Peptides and methods for preventing ischemic tissue injury
CA2812704C (en) Formulations for bovine granulocyte colony stimulating factor and variants thereof